IRIS
BOGLIONE, Lucio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.276
NA - Nord America 2.684
AS - Asia 2.471
SA - Sud America 674
AF - Africa 96
Continente sconosciuto - Info sul continente non disponibili 17
Totale 9.218
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.596
RU - Federazione Russa 1.061
IE - Irlanda 945
SG - Singapore 778
CN - Cina 524
BR - Brasile 516
VN - Vietnam 434
HK - Hong Kong 413
SE - Svezia 310
IT - Italia 255
UA - Ucraina 222
DE - Germania 157
FR - Francia 155
AR - Argentina 73
ID - Indonesia 63
BD - Bangladesh 56
CA - Canada 40
IN - India 40
GB - Regno Unito 39
KR - Corea 32
MX - Messico 31
ZA - Sudafrica 27
EC - Ecuador 25
FI - Finlandia 23
BE - Belgio 20
IQ - Iraq 20
BJ - Benin 19
JP - Giappone 19
VE - Venezuela 18
PY - Paraguay 17
CO - Colombia 15
EU - Europa 15
AT - Austria 13
MA - Marocco 12
NL - Olanda 12
ES - Italia 10
TR - Turchia 10
PL - Polonia 9
RO - Romania 8
SA - Arabia Saudita 8
CZ - Repubblica Ceca 7
DZ - Algeria 7
KE - Kenya 7
NP - Nepal 7
UZ - Uzbekistan 7
CL - Cile 6
EG - Egitto 6
IL - Israele 6
IR - Iran 6
PH - Filippine 6
TN - Tunisia 6
BG - Bulgaria 5
LT - Lituania 5
PK - Pakistan 5
TH - Thailandia 5
AE - Emirati Arabi Uniti 4
AZ - Azerbaigian 4
ET - Etiopia 4
JM - Giamaica 4
JO - Giordania 4
KZ - Kazakistan 4
CH - Svizzera 3
KG - Kirghizistan 3
LB - Libano 3
QA - Qatar 3
RS - Serbia 3
TT - Trinidad e Tobago 3
AL - Albania 2
DK - Danimarca 2
GT - Guatemala 2
HN - Honduras 2
HU - Ungheria 2
MD - Moldavia 2
NO - Norvegia 2
PA - Panama 2
PE - Perù 2
TW - Taiwan 2
XK - ???statistics.table.value.countryCode.XK??? 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BO - Bolivia 1
BW - Botswana 1
CR - Costa Rica 1
CY - Cipro 1
DM - Dominica 1
GA - Gabon 1
GE - Georgia 1
GM - Gambi 1
LV - Lettonia 1
MK - Macedonia 1
ML - Mali 1
MY - Malesia 1
PS - Palestinian Territory 1
PT - Portogallo 1
SN - Senegal 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TG - Togo 1
UG - Uganda 1
Totale 9.217
Salva come PNG Salva come JPEG
Città #
Dublin 929
Hong Kong 410
Jacksonville 374
Singapore 309
San Jose 257
Beijing 167
Ashburn 161
Council Bluffs 145
Ho Chi Minh City 143
Moscow 130
Lauterbourg 122
Wilmington 120
Lawrence 118
Princeton 118
Chandler 108
San Mateo 106
Hanoi 88
Los Angeles 86
Columbus 65
Munich 56
São Paulo 54
Buffalo 43
Santa Clara 39
Redondo Beach 31
Seoul 31
Dong Ket 30
Jakarta 30
New York 29
Dallas 27
Piemonte 26
Ann Arbor 25
Orem 25
Boardman 23
Brussels 19
Cotonou 19
Tianjin 19
Houston 17
Novara 17
Frankfurt am Main 16
Montreal 16
Nuremberg 16
Tokyo 16
Da Nang 15
Milan 15
Shanghai 15
Haiphong 14
Norwalk 14
Rio de Janeiro 14
Turin 14
Guangzhou 13
Helsinki 13
Johannesburg 13
Mexico City 13
Toronto 12
Dhaka 11
Falkenstein 11
Amsterdam 10
Denver 10
Guayaquil 10
Porto Alegre 10
San Francisco 10
Thái Bình 10
Belo Horizonte 9
Brooklyn 9
Chennai 9
Hangzhou 9
London 9
Quito 9
Turku 9
Andover 8
Biên Hòa 8
Hải Dương 8
Warsaw 8
Brasília 7
Caracas 7
Casablanca 7
Manchester 7
Tashkent 7
Alessandria 6
Baghdad 6
Brno 6
Cape Town 6
Chicago 6
Curitiba 6
Fairfield 6
Horia 6
Nairobi 6
Naples 6
Rome 6
San Diego 6
Vienna 6
West Jordan 6
Woodbridge 6
Asunción 5
Atlanta 5
Buenos Aires 5
Cairo 5
Campinas 5
Franca 5
Grafing 5
Totale 5.082
Salva come PNG Salva come JPEG
Nome #
Fatality rate and predictors of mortality in an Italian cohort of hospitalized COVID-19 patients 257
Simple Parameters from Complete Blood Count Predict In-Hospital Mortality in COVID-19 200
Contribution of Atrial Fibrillation to In-Hospital Mortality in Patients With COVID-19 180
A UHPLC-MS/MS method for the quantification of currently used direct antiviral agents in human plasma and evaluation of "normalized matrix effect" 108
Antiviral therapy in patients with HBV treated for tuberculosis: a forgotten issue 101
VDR gene polymorphisms impact on anemia at 2 week of anti-HCV therapy: a possible mechanism for early RBV-induced anemia 101
A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir 100
A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma 100
Coinfection with other respiratory pathogens in COVID-19 patients 97
Association of vitamin D pathway SNPs and clinical response to interferon in a cohort of HBeAg-negative patients 95
A Possible Role of Therapeutic Drug Monitoring in Virological Breakthrough during Simeprevir and PEG-IFN Treatment in HCV-4 93
Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients 93
A Case of Imported JE Acquired During Short Travel in Vietnam. Are Current Recommendations About Vaccination Broader? 93
Evaluation of intracellular and plasma pharmacokinetics, pharmacogenetics and clinical features in HBV e antigen-negative patients treated with entecavir 93
Clinical Characteristics and Outcomes in Patients with Chronic HBV Infection and Hospitalized for COVID-19 Pneumonia: A Retrospective Cohort Study 92
Antiviral treatment with pegylated interferon and clinical outcomes in a cohort of immigrants patients affected by hepatitis delta: A retrospective analysis 92
Vitamin D pathway polymorphisms impact on HBV interferon treatment outcomes in a cohort of HBeAg negative patients 92
A concentration-dependent pharmacokinetic interaction with telaprevir increases ribavirin concentrations and leads to higher haemoglobin drop 91
Characterization of resistance profiles in HCV 2-3-4 DAA-naïve and DAA-experienced infected patients in Italy 89
Ceftobiprole perspective: Current and potential future indications 89
[Primary soft tissue and tenosynovial tuberculosis after needlestick injury in a surgeon] 88
ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy 87
Characterization of a novel chemiluminescent enzyme immunoassay for the quantitation of antibodies to hepatitis B core antigen class IgG and correlation with intrahepatic HBV covalently-closed-circular DNA 87
Development and validation of a useful UPLC-MS/MS method for quantification of total and phosphorylated-ribavirin in peripheral blood mononuclear cells of HCV+ patients 85
Treatment optimization of naïve HCV-1 patients using IL28B, RVR and fibrosis stage 84
Prevalenza e fattori di rischio dell'insorgenza di psicosi acuta 59 nei pazienti anziani ospedalizzati per infezione da Sars-COV-2: studio retrospettivo 83
Lo studio filologico applicato alla descrizione della “pestilenza” di Atene di Tucidide: dall’analisi del testo agli aspetti di epidemiologia e malattie infettive 82
A rare SARS-CoV-2 complication: Candida spondylodiscitis following SARS-CoV-2 infection—two case reports 81
Are detectable sofosbuvir trough concentrations predictive of virological failure during anti-HCV treatment? Preliminary evidences from the KINETI-C study 81
EPATITE CRONICA DA HBV DI GENOTIPO E NELLA POPOLAZIONE IMMIGRATA PROVENIENTE DALL'AFRICA OCCIDENTALE 80
Role of pharmacogenetic in ribavirin outcome prediction and pharmacokinetics in an Italian cohort of HCV-1 and 4 patients 80
Sequential therapy with entecavir and peginterferon alpha in chronic hepatitis B: for many but not for all? 79
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 79
Virological response and safety in a cohort of immigrant patients affected by chronic hepatitis delta treated with PEG-IFN 79
F-33 Early ribavirin plasma concentration and ITPA polymorphisms as determinants of anemia after one month of anti-HCV therapy 78
The proper use of corticosteroids for 2019-nCov pneumonia: Towards promising results? 78
Prospective evaluation of qHBsAg decline in patients affected by chronic hepatitis B, E genotype, treated with entecavir or tenofovir 78
Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B 77
Retreatment with sofosbuvir/velpatasvir in cirrhotic patients with genotype-4 who failed a previous interferon-free regimen: A case series 77
Long-COVID syndrome in hospitalized patients after 2 years of follow-up 76
Daclatasvir Plasma Levels in a Cohort of Patients with Hepatitis C Virus Infection Taking Methadone: A Prospective Analysis 75
Combination therapy in chronic hepatitis B: what are the real benefits? 75
Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir 75
Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy 75
UPLC-MS/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells 74
Development and validation of an UPLC MS-MS method for the quantification of new direct antiretroviral agents simeprevir, daclatasvir sofosbuvir and its metabolite GS-332007 in human plasma 74
Risk for SARS-CoV-2 Infection in Healthcare Workers, Turin, Italy 74
Risk factors and incidence of long-COVID syndrome in hospitalized patients: does remdesivir have a protective effect? 73
Behavioural health issues in post coronavirus disease (COVID) syndrome and suicide risk: a narrative review 72
HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naïve patients: consideration for HCV genotyping resistance testing 72
Role of simeprevir plasma concentrations in HCV treated patients with dermatological symptoms 71
Visceral leishmaniasis in a patient with active HBV/HDV co-infection 71
Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: a prospective study 71
High four weeks’ entecavir plasma concentration is a negative predictor of HBV DNA drop after three months of therapy 70
Vitamin D pathway genetic variants are able to influence sofosbuvir and its main metabolite pharmacokinetics in HCV mono-infected patients 69
Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens 69
Risk Factors for Mortality in COVID-19 Hospitalized Patients in Piedmont, Italy: Results from the Multicenter, Regional, CORACLE Registry 69
Clinical characteristics and outcomes in hospitalized patients with West Nile neuroinvasive disease: A case-series analysis 68
The co-administration of telaprevir increases ribavirin plasma and intra-erythrocytic concentrations, causing higher onset of anemia 68
Liver involvement and mortality in COVID-19: A retrospective analysis from the CORACLE study group 68
Epidemiology, patient profile, and health care resource use for hepatitis C in Italy 67
Early ribavirin plasma concentrations as predictor of anemia onset after one month of anti-HCV therapy in ITPA stratified population 67
Role of IL28B genotype in the liver stiffness increase in untreated patients with chronic hepatitis C 67
Vitamin D pathway gene variants and HCV-2/3 therapy outcomes 66
UPLC-MS/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: Entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients 66
Triple or dual therapy for HCV-1 naive patients? Optimizing selection tools 66
Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E 66
Serological and virological response in patients with hepatitis B virus genotype E treated with entecavir or tenofovir: a prospective study 66
Real-World Outcomes of Neutralizing Monoclonal Antibody Treatment in Patients Affected by Nosocomial Coronavirus Disease 2019 65
Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors 65
Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy 65
Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon 65
Reasons to wait or to treat naive patients affected by chronic hepatitis C with low fibrosis stage and genotypes 2 or 3 65
Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon 65
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 65
Role of the early short-course corticosteroids treatment in ARDS caused by COVID-19: A single-center, retrospective analysis 64
Identification of naïve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms 64
Predictors of Mortality in Patients with COVID-19 Infection in Different Health- Care Settings: A Retrospective Analysis from a CORACLE Study Group 63
Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment 63
Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon 63
Response to: Efficacy and safety of hydroxychloroquine/chloroquine against SARS-CoV-2 infection: A systematic review and meta-analysis 63
Plasmatic and intracellular concentration of entecavir during treatment of a symptomatic flare in HBV-HDV decompensated cirrhosis 62
Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics 62
Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study 62
Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir 62
Efficacy and safety of interferon-free regimens in patients affected by chronic hepatitis C and psychiatric disorders 62
Pharmacogenetic analysis of hepatitis C virus related mixed cryoglobulinemia 62
Remdesivir treatment in hospitalized patients affected by COVID-19 pneumonia: a case-control study 62
Real-Life Experience of Molnupiravir in Hospitalized Patients Who Developed SARS-CoV2-Infection: Preliminary Results from CORACLE Registry 61
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy 61
Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy 61
Letter: liver involvement and mortality in COVID-19—the role of anti-viral therapy should be considered 61
Role of plasmatic and urinary concentration of tenofovir disoproxil fumarate in a cohort of patients affected by chronic hepatitis B 61
Entecavir plasma concentrations are inversely related to HBV-DNA decrease in a cohort of treatment-naïve patients with chronic hepatitis B 60
Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes 60
Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study 60
Early ribavirin concentration is a critical response factor in the sub-population of patients infected by HCV-1 and unfavourable IL28B genotype 60
Factors Influencing the Intracellular Concentrations of the Sofosbuvir Metabolite GS-331007 (in PBMCs) at 30 Days of Therapy 60
The E genotype of hepatitis B: Clinical and virological characteristics, and response to interferon 59
Extended duration of treatment with peginterferon alfa-2a in patients with chronic hepatitis B, HBeAg-negative and E genotype: A retrospective analysis 59
Totale 7.831
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.826
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.826
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202140 0 0 0 0 0 0 0 0 0 0 0 40
2021/2022673 8 10 126 47 20 21 27 16 93 24 120 161
2022/20231.564 135 111 89 24 36 89 33 61 913 13 44 16
2023/2024441 26 19 18 9 64 6 116 15 13 10 7 138
2024/20251.438 14 11 100 25 14 67 186 157 432 201 40 191
2025/20264.487 176 206 445 828 278 304 617 670 278 314 168 203
Totale 9.368